IL158967A0 - Identifying parasitic fungi of the organism, and treatment thereof - Google Patents

Identifying parasitic fungi of the organism, and treatment thereof

Info

Publication number
IL158967A0
IL158967A0 IL15896702A IL15896702A IL158967A0 IL 158967 A0 IL158967 A0 IL 158967A0 IL 15896702 A IL15896702 A IL 15896702A IL 15896702 A IL15896702 A IL 15896702A IL 158967 A0 IL158967 A0 IL 158967A0
Authority
IL
Israel
Prior art keywords
organism
treatment
parasitic fungi
identifying
identifying parasitic
Prior art date
Application number
IL15896702A
Other languages
English (en)
Original Assignee
Roumen Antonov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0106775A external-priority patent/FR2825024B1/fr
Priority claimed from FR0109203A external-priority patent/FR2827173B3/fr
Application filed by Roumen Antonov filed Critical Roumen Antonov
Publication of IL158967A0 publication Critical patent/IL158967A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56961—Plant cells or fungi

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
IL15896702A 2001-05-23 2002-05-23 Identifying parasitic fungi of the organism, and treatment thereof IL158967A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0106775A FR2825024B1 (fr) 2001-05-23 2001-05-23 Identification de champignons parasites de l'organisme, et leur traitement
FR0109203A FR2827173B3 (fr) 2001-07-11 2001-07-11 Identification de champignons parasites de l'organisme, et leur traitement
PCT/FR2002/001739 WO2002094287A2 (fr) 2001-05-23 2002-05-23 Identification de champignons parasites de l'organisme, et traitement des maladies liees

Publications (1)

Publication Number Publication Date
IL158967A0 true IL158967A0 (en) 2004-05-12

Family

ID=26213022

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15896702A IL158967A0 (en) 2001-05-23 2002-05-23 Identifying parasitic fungi of the organism, and treatment thereof

Country Status (18)

Country Link
US (1) US20040198633A1 (sk)
EP (1) EP1389120B1 (sk)
KR (1) KR20040018377A (sk)
CN (1) CN1518451A (sk)
BG (1) BG66299B1 (sk)
BR (1) BR0209869A (sk)
CA (1) CA2448045A1 (sk)
CZ (1) CZ20033145A3 (sk)
EE (1) EE200300572A (sk)
HU (1) HUP0400035A2 (sk)
IL (1) IL158967A0 (sk)
NO (1) NO20035188D0 (sk)
NZ (1) NZ529764A (sk)
PL (1) PL367700A1 (sk)
RU (1) RU2003136777A (sk)
SK (1) SK14372003A3 (sk)
WO (1) WO2002094287A2 (sk)
ZA (1) ZA200309122B (sk)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9314524B2 (en) * 2007-12-31 2016-04-19 Calla Therapeutics Llc Topical formulations of Flucytosine
CN103044376A (zh) * 2012-12-15 2013-04-17 青岛农业大学 桑黄菌中吡喃酮的分离技术
CN116515641B (zh) * 2023-04-26 2023-09-29 吉林农业大学 一株珊瑚状猴头菌及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2786781A (en) * 1954-11-04 1957-03-26 Olin Mathieson Process of recovering nystatin
US2908611A (en) * 1954-12-28 1959-10-13 Olin Mathieson Amphotericin b, its production, and its salts
US3714348A (en) * 1970-12-02 1973-01-30 Schmid Inc Julius Method for controlling absorption of cholesterol
US4025620A (en) * 1975-10-22 1977-05-24 Leo Pharmaceutical Products Ltd., A/S Treatment of canine otitis and composition therefor
US4491588A (en) * 1982-03-31 1985-01-01 University Of Tennessee Research Corporation Treatment of psoriasis and seborrheic dermatitis with imidazole antibiotics
GB9320744D0 (en) * 1992-11-04 1993-12-01 Zeneca Ltd Oxa and thiadiazole derivatives
US5358959A (en) * 1993-02-18 1994-10-25 President And Fellows Of Harvard University Methods for treating arteriosclerosis
EP0771205A2 (de) * 1994-06-28 1997-05-07 Dr. Zerle Gmbh Neue klinische anwendungen von polyen-makroliden
US5914239A (en) * 1995-11-15 1999-06-22 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Diagnosis of fungal infections, and a chitin-binding lectin useful in such diagnoses
WO2001014592A2 (en) * 1999-08-25 2001-03-01 Clarity Biosciences, Inc. Identifying organisms by detecting intronic nucleic acid or encoded proteins

Also Published As

Publication number Publication date
CA2448045A1 (fr) 2002-11-28
EP1389120B1 (fr) 2012-08-01
US20040198633A1 (en) 2004-10-07
WO2002094287A3 (fr) 2003-09-25
BR0209869A (pt) 2004-04-20
EP1389120A2 (fr) 2004-02-18
BG108375A (bg) 2005-01-31
BG66299B1 (bg) 2013-03-29
ZA200309122B (en) 2004-11-24
PL367700A1 (en) 2005-03-07
SK14372003A3 (sk) 2004-05-04
KR20040018377A (ko) 2004-03-03
CN1518451A (zh) 2004-08-04
NO20035188D0 (no) 2003-11-21
CZ20033145A3 (cs) 2004-10-13
RU2003136777A (ru) 2005-04-10
WO2002094287A2 (fr) 2002-11-28
NZ529764A (en) 2005-08-26
EE200300572A (et) 2004-02-16
HUP0400035A2 (hu) 2004-04-28

Similar Documents

Publication Publication Date Title
AP2004003002A0 (en) azabicyclic-substituted fused-heteroaryl compoundsfor the treatment of disease.
AU2002346379A1 (en) Dilation catheter assembly and related methods
IL158618A0 (en) Biological pacemaker
AU2002255248A1 (en) Diagnosis, treatment and research of mental disorders
PL370163A1 (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
AU2002220266A1 (en) Methods for the identification and the treatment of cardiovascular disease
WO2003063725A3 (en) Methods of preventing and treating flavivirus infection in animals
AU2002319286A1 (en) Skin treatment
IL158967A0 (en) Identifying parasitic fungi of the organism, and treatment thereof
GB0130763D0 (en) Treatment methods
AU2002304492A1 (en) Identifying parasitic fungi of the organism, and treatment thereof
GB0103031D0 (en) Novel treatment
ZA200204018B (en) Combination treatment for depression and anxiety.
ZA200103250B (en) The treatment of immunomodulatory related and other diseases or conditions.
AP2004002980A0 (en) The treatment of lipodystrophy.
GB0130694D0 (en) Treatment
AU2002365654A1 (en) Treatment of diseases via the skin
IL144389A0 (en) Medical database
FR2827173B3 (fr) Identification de champignons parasites de l'organisme, et leur traitement
GB0128813D0 (en) Medical treatment
GB0127267D0 (en) Medical treatment
GB0106983D0 (en) Medical treatment
GB0127271D0 (en) Medical treatment
AU2002308074A1 (en) Skin treatment